SAN DIEGO / May 02, 2023 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
BofA Securities 2023 Health Care Conference
Fireside Chat: Wednesday, May 10, 2023 at 2:20 p.m. Eastern Time in Las Vegas, NV
The JMP Securities Life Sciences Conference
Fireside Chat: Tuesday, May 16, 2023 at 2:30 p.m. Eastern Time in New York, NY
2023 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 17, 2023 at 1:35 p.m. Eastern Time in New York, NY
Live webcasts of the presentations will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For almost 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
Last Trade: | US$20.88 |
Daily Change: | -0.07 -0.33 |
Daily Volume: | 1,872,532 |
Market Cap: | US$3.470B |
June 25, 2025 May 27, 2025 May 07, 2025 March 03, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load